ReviewIranian journal of basic medical sciences2019
Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review.
Review in Iranian journal of basic medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Thromboangiitis Obliterans (Buerger's Disease): A Young Woman's Rare Case and Current Knowledge.The International journal of angiology : official publication of the International College of Angiology, Inc · 2026Article
- Effect of IV Iloprost on Distal Flow in Buerger's Disease: Correlation with CT Perfusion.Journal of clinical medicine · 2026Article
- Investigation of the molecular mechanism of Xiaoluo Wan in thyroid-associated ophthalmopathy: network analysis and in vivo study.Hereditas · 2025Article
- Oxidative stress in vascular surgical diseases: mechanisms, impacts and therapeutic perspectives.Frontiers in pharmacology · 2025Review
- Integration of machine learning and bulk sequencing revealed exosome-related gene FOSB was involved in the progression of abdominal aortic aneurysm.Frontiers in cell and developmental biology · 2025Article
- Exploring the oxidative and inflammatory markers landscape in Buerger's disease: A comparative analysis.Journal of education and health promotion · 2025Article
- Comparative Analysis of Transcriptome Profiles in Patients with Thromboangiitis Obliterans.Genes · 2023Article
- Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways.Frontiers in pharmacology · 2022Article
- Integrated analysis of long non-coding RNA-microRNA-mRNA competing endogenous RNAregulatory networks in thromboangiitis obliterans.Bioengineered · 2021Article
- Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences.Diagnostics (Basel, Switzerland) · 2021Review
- Predictive value of serum VEGF, IL-1 and TNF-α in the treatment of thromboangiitis obliterans by revascularization.Experimental and therapeutic medicine · 2020Article
- The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease).Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thromboangiitis obliterans (TAO) is a thrombotic-occlusive as well as an inflammatory peripheral vascular disease with unknown etiology. Recent evidence has supported the immunopathogenesis of the disease, however, the factors contributing to the altered immune function and vascular tissue inflammation are still unclear. This review was intended to collate the more current knowledge on the regulatory molecules involved in TAO from an immunoreactive perspective. The homeostasis of the immune system as well as a variety of progenitor cell populations appear to be affected during TAO and these alterations are associated with intrinsic signaling defects that are directing to an improved understanding of the crosstalk between angiogenesis and the immune system, as well as the potential of new co-targeting strategies applying both immunotherapy and angiogenic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.